Dror Ortho-Design, Inc. Launches ZSMILE User Experience Trial
Dror Ortho-Design, Inc. (“Dror” or the “Company”) (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people’s smiles by straightening teeth using pulsating air delivered by a single custom-made smart aligner, today announced…
NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)
Neurim Pharmaceuticals (“Neurim”) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending an extension to the existing indication to include the treatment of Insomnia in children with…
Rusan Pharma’s API Plant in Ankleshwar (India)Receives USFDA GMP Approval
RUSAN PHARMA PRIVATE LIMITED,a pharmaceutical company based in India specializing in the area of addiction treatment and pain management, recently announced that the United States Food and Drug Administration (US FDA) has granted Good Manufacturing Practice (GMP) approval for its…
SHINE Technologies Showcases FLARE™, the World’s Most Powerful Continuous Fusion Neutron System
SHINE Technologies, a next-generation fusion company, will showcase FLARE™, the world’s most powerful continuous fusion neutron system, at the IEEE Nuclear & Space Radiation Effects Conference (NRSEC) and at the Technology of Fusion Energy Meeting (TOFE). FLARE, which stands for “Fusion Linear Accelerator for Radiation…
Elite PR joins Global Health Marketing & Communications (GHMC) as Exclusive Taiwan Agency
Global Health Marketing & Communications (GHMC), the largest and most robust network of independent healthcare agencies worldwide, today announced the addition of Elite PR, a Taiwan-based communications agency. The addition strengthens GHMC’s offerings in the Asia-Pacific region and expands the…
PharmaLogic announces opening of radiopharmaceutical production facility in New York City
PharmaLogic Holdings Corp., (“PharmaLogic” or “the company”), a world-class contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, celebrates the opening of its radiopharmaceutical production and research facility in the Bronx, New York. Acquired in 2022, the facility has undergone…
HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device
WAT Medical Enterprise achieves a major milestone: HeadaTerm 2 receives the OTC clearance from the U.S. Food and Drug Administration (FDA), making it one of the only wearable anti-migraine devices that is available without a prescription in the U.S. Using neuromodulation…
First Patient Treated in Phase 2 GvHD Trial
Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). CYP-001 is…
Father of Exactech Employee Receives First Ankle Replacement Using Activit-E™ Polyethylene
Exactech Quality Control Manager Wesley Garrett experienced a full circle moment in both his professional and personal life when his father received an Activit-E™ polyethylene insert after following the company’s polyethylene initiatives for six years. In 2018, Garrett was hired as an intern to…
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in…
